PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.94 EUR | +0.17% |
|
-0.68% | -36.09% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.935
EUR
Average target price
6.85
EUR
Spread / Average Target
+133.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.97% | 103B | |
| +2.15% | 96.56B | |
| +1.72% | 22.61B | |
| -17.53% | 21.18B | |
| -4.50% | 19.07B | |
| -41.75% | 16.53B | |
| -25.41% | 14.46B | |
| +2.13% | 13.25B | |
| +22.48% | 11.1B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Erytech Pharma Gets US Patent For Methioninase, Asparaginase in Solid Tumor Treatment
